Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.

Zwaginga JJ, van der Holt B, Te Boekhorst PA, Biemond BJ, Levin MD, van der Griend R, Brand A, Zweegman S, Pruijt HF, Novotny VM, Vreugdenhil A, de Groot MR, de Weerdt O, van Pampus EC, van Maanen-Lamme TM, Wittebol S, Schipperus MR, Silbermann MH, Huijgens PC, Luten M, Hollestein R, Brakenhoff JA, Schrama JG, Valster FA, Velders GA, Koene HR; Dutch HOVON 64 study group.

Haematologica. 2015 Mar;100(3):e90-2. doi: 10.3324/haematol.2014.110213. Epub 2014 Nov 25. No abstract available.

2.

Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch.

Boers-Doets CB, Gelderblom H, Lacouture ME, Bredle JM, Epstein JB, Schrama NA, Gall H, Ouwerkerk J, Brakenhoff JA, Nortier JW, Kaptein AA.

Eur J Oncol Nurs. 2013 Dec;17(6):802-7. doi: 10.1016/j.ejon.2013.03.004. Epub 2013 Apr 6.

PMID:
23571183
3.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

4.

Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.

Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H.

Oncologist. 2012;17(1):135-44. doi: 10.1634/theoncologist.2011-0111. Epub 2011 Dec 29. Review.

5.

[Osteolytic foci: cancer or not?].

Brakenhoff JA, Bakker PJ, de Wit R, Veenhof CH.

Ned Tijdschr Geneeskd. 1989 Feb 25;133(8):377-81. Dutch. No abstract available.

PMID:
2648175
6.

[Side effects of cytostatic agents; treatment recommendations].

Brakenhoff JA, Bakker PJ, Veenhof CH.

Ned Tijdschr Geneeskd. 1989 Feb 11;133(6):286-9. Dutch. No abstract available.

PMID:
2927543
7.

Determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in biological fluids by reverse-phase high pressure liquid chromatography.

Wiltink EH, Stekkinger P, Brakenhoff JA, Danner SA.

Pharm Weekbl Sci. 1987 Oct 16;9(5):261-4.

PMID:
3501569
8.

Mean platelet volume in myocardial infarction.

van der Lelie J, Brakenhoff JA.

Br Med J (Clin Res Ed). 1983 Nov 12;287(6403):1471. No abstract available.

Supplemental Content

Loading ...
Support Center